Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 7/20 | 0.75 |
| ▸ | MME | P08473 | 2/20 | 0.75 |
| ▸ | ACE | P12821 | 2/20 | 0.75 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | CCR4 | P51679 | 5/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5723207 | 0.92 | MME (0.63) | ECE1MMEACEMMP2 | |
| SCHEMBL5723079 | 0.92 | ECE1 (0.78) | ECE1MMEACEHCRTR1HCRTR2 | |
| SCHEMBL5723077 | 0.92 | ECE1 (0.78) | ECE1MMEACEHCRTR1HCRTR2 | |
| SCHEMBL5723238 | 0.89 | ECE1 (0.71) | ECE1MMEACEHCRTR1HCRTR2 | |
| SCHEMBL5722884 | 0.88 | ECE1 (0.75) | ECE1MMEACEHCRTR1HCRTR2 | |
| SCHEMBL5723188 | 0.88 | ECE1 (0.75) | ECE1MMEACEHCRTR1HCRTR2 | |
| SCHEMBL5723003 | 0.87 | ECE1 (0.69) | ECE1MMEACEHCRTR1HCRTR2 | |
| SCHEMBL5723283 | 0.87 | ECE1 (0.68) | ECE1MMEACEHCRTR1HCRTR2 | |
| SCHEMBL5723300 | 0.87 | ECE1 (0.84) | ECE1MMEACEHCRTR1HCRTR2 | |
| SCHEMBL5724060 | 0.86 | ECE1 (0.58) | ECE1MMEACEHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317428-B1 | PYRROLIDINE-2-CARBOXYLIC ACID HYDRAZIDE DERIVATIVES FOR USE AS METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2006-04-19 | — | — | EP | claimed |
| EP-1317428-A1 | PYRROLIDINE-2-CARBOXYLIC ACID HYDRAZIDE DERIVATIVES FOR USE AS METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-11 | — | — | EP | claimed |
| US-6444829-B1 | (2S,4R)-4-MERCAPTO-1-(NAPHTHALENE-2-SULFONYL)-PYRROLIDINE-2 -CARBOXYLIC ACID N'-ISOBUTYL-N'-(4-METHYL-BENZENESULFONYL)-HYDRAZIDE, FOR EXAMPLE; INHIBITORS OF METALLOPROTEASES, E.G. ZINC PROTEASES; VASODILATORS | HOFFMANN-LA ROCHE INC. | 2002-09-03 | — | — | US | claimed |
| US-20020040048-A1 | PYRROLIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-04-04 | — | — | US | claimed |
| WO-2002006224-A1 | PYRROLIDINE-2-CARBOXYLIC ACID HYDRAZIDE DERIVATIVES FOR USE AS METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | claimed |
| EP-1317428-B1 | PYRROLIDINE-2-CARBOXYLIC ACID HYDRAZIDE DERIVATIVES FOR USE AS METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2006-04-19 | — | — | EP | disclosed |
| EP-1317428-A1 | PYRROLIDINE-2-CARBOXYLIC ACID HYDRAZIDE DERIVATIVES FOR USE AS METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-11 | — | — | EP | disclosed |
| US-6444829-B1 | (2S,4R)-4-MERCAPTO-1-(NAPHTHALENE-2-SULFONYL)-PYRROLIDINE-2 -CARBOXYLIC ACID N'-ISOBUTYL-N'-(4-METHYL-BENZENESULFONYL)-HYDRAZIDE, FOR EXAMPLE; INHIBITORS OF METALLOPROTEASES, E.G. ZINC PROTEASES; VASODILATORS | HOFFMANN-LA ROCHE INC. | 2002-09-03 | — | — | US | disclosed |
| US-20020040048-A1 | PYRROLIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-04-04 | — | — | US | disclosed |
| WO-2002006224-A1 | PYRROLIDINE-2-CARBOXYLIC ACID HYDRAZIDE DERIVATIVES FOR USE AS METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040048-A1 | PYRROLIDINE COMPOUNDS | PREP, PEPD, MMP3 | ECE1 5/4885MME 56/4885ACE 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.